Current trends in the management of pancreatic cystic neoplasms in Korea: a national survey

Hyung Ku Chon¹, Sung Hoon Moon², Sang Wook Park³, Woo Hyun Paik⁴, Chang Nyol Paik⁵, Byoung Kwan Son⁶, Tae Jun Song⁷, Dong Won Ahn⁸, Eaum Seok Lee⁹, Yun Nah Lee¹⁰, Yoon Suk Lee¹¹, Jae Min Lee¹², Tae Joo Jeon¹³, Chang Hwan Park¹⁴, Kwang Bum Cho¹⁵, and Dong Wook Lee¹⁶

Department of Internal Medicine, ¹Institute of Wonkwang Medical Science, Wonkwang University College of Medicine, Iksan; ²Hallym University College of Medicine, Anyang; ³Kwangju Christian Hospital, Gwangju; ⁴Seoul National University College of Medicine, Seoul; ⁵St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Suwon; ⁶Eulji University College of Medicine, Seoul; ⁷University of Ulsan College of Medicine, Seoul; ⁸Seoul National University Boramae Medical Center, Seoul; ⁹Chungnam National University College of Medicine, Daejeon; ¹⁰ Soonchunhyang University School of Medicine, Bucheon; ¹¹Inje University Ilsan Paik Hospital, Goyang; ¹²Korea University College of Medicine, Seoul; ¹³Inje University Sanggye Paik Hospital, Seoul; ¹⁴Chonnam National University Medical School, Gwangju; ¹⁵Keimyung University Dongsan Medical Center, Keimyung University School of Medicine, Daegu; ¹⁶Daegu Catholic University School of Medicine, Daegu, Korea

Pancreatic cystic neoplasms in Korea: a national survey

Preferred guideline: 2012/2017 IAP guidelines (65.2%)

Imaging modalities
- First line: Gadolinium-enhanced MRI/MRCP (40.9%)
- Subsequent tool: Contrast enhanced CT (58.3%)

Routine performing EUS-FNA of PCNs with suspicious mural nodule: 74%

Recommendation of surgery
- High risk stigmata: 94% recommend surgery
- Worrisome feature: 18.3% recommend surgery

Continuation of surveillance: more than 5 years (96.5%)

Clinicians’ management strategies of pancreatic cystic neoplasms (PCNs) slightly vary according to their preferred guideline, experience, or type of hospital.

Development of evidence-based guidelines for pancreatic cystic neoplasms that fit the Korean practice is needed.
INTRODUCTION

Pancreatic cystic neoplasms (PCNs) are recognized, ranging from 2.6% to 15% in general populations, due to the increased use of high-quality imaging modalities in clinical practice [1,2]. PCNs are a heterogeneous group of disorders with a wide range of benign, borderline, or malignant pathologic features [3]. Most PCNs have a relatively indolent course, but others should be resected due to the risk of malignant transformation [4]. Despite considerable investigations, their actual biological behavior or natural history remains unclear. Furthermore, accurate selection of patients with PCNs for surveillance versus operative management remains difficult, and the accuracy of preoperative PCN classification comparing post-operative diagnosis may be suboptimal [5]. Regarding these uncertainties, even though malignant transformation is very rare, PCNs may present significant challenges and anxiety for both the patients and the healthcare providers.

Practice guidelines for PCNs have been recommended to ensure standardized surveillance and treatment strategies. Such guidelines were issued in 2017 by the International Association of Pancreatology (IAP), and, more recently, in 2018, at the United States of America and Europe [4,6,7]. However, these guidelines contain recommendations, including expert opinions, based on relatively low-level evidence and on retrospective studies that consider only surgically treated patients. Moreover, several aspects on treatment and surveillance strategies differ among the guidelines. Therefore, it is thought that the management of patients with PCN in real clinical practice may vary depending on clinicians’ guideline preference, experience, or type of hospital. To date, there have been few studies about the practical management of PCNs. This nationwide study aimed to investigate the current practice patterns in the management of PCNs in Korea.

METHODS

Study design and participants

This study was conducted from December 2019 to February 2020. The survey was distributed by email and administered through a web-based survey platform (SurveyMonkey, San Mateo, CA, USA). Potential participants were identified using the database from the Korean Pancreatobiliary Association (KPBA). Survey participants were informed that the survey required 5 to 10 minutes to complete. During the study period, reminder emails were sent every week for participants. All completed data were anonymized and analyzed using a
web-based software platform.

Survey creation and electronic survey contents
The current validity of the survey was determined through the literature review and was based on the reviews of expert members of Policy-Quality management in KPBA. The final survey was a 20-item questionnaire (Appendix 1). The survey items included baseline characteristics regarding age, gender, subspecialty, and type of hospital. Clinicians’ preferred guidelines, clinical application of endoscopic ultrasound (EUS), practice patterns regarding the choice of imaging modalities, interval of surveillance, and the criteria for surgical resection were also included. This study was approved by the Institutional Review Board (IRB) at Wonkwang University Hospital (IRB No. WKUH 2020-06-019-001). In accordance with IRB guidelines for anonymous surveys, the need for documentation of informed consent among participants was waived.

Statistical analysis
All analyses were performed with SPSS version 24.0 (IBM Co., Armonk, NY, USA). Data were reported as mean ± standard deviation, and proportion. A Student’s t test was used for comparison of continuous data, and the chi-square test or Fisher’s exact test was used for comparison of categorical variables. A p value < 0.05 was considered to indicate statistical significance.

RESULTS
Baseline characteristics
The survey was distributed to 1,010 email addresses through the KPBA membership directory, and 115 (11.4%) were completed. We excluded 25 (2.4%) that were partially completed. The demographic characteristics of the respondents are shown in Table 1. The majority of respondents were male (96.5%), gastroenterologists (95.7%), working in a tertiary/academic (TA) medical center (72.2%), and per-

Table 1. Demographics of the respondents

| Characteristic                  | Overall (n = 115) | TA medical center (n = 83) | PS care center (n = 32) | p value |
|--------------------------------|-------------------|---------------------------|------------------------|---------|
| Sex, male/female               | 111/4             | 79/4                      | 32/0                   | 0.57    |
| Age, yr                        |                   |                           |                        | 0.93    |
| 31–40                          | 33 (28.7)         | 24 (39.8)                 | 9 (28.1)               |         |
| 41–50                          | 48 (41.7)         | 33 (39.8)                 | 15 (46.9)              |         |
| 51–60                          | 29 (25.2)         | 22 (26.5)                 | 7 (21.9)               |         |
| 60 or more                     | 5 (4.3)           | 4 (4.8)                   | 1 (3.1)                |         |
| Specialty                      |                   |                           |                        | 0.32    |
| Gastroenterologist             | 110 (95.7)        | 78 (94.0)                 | 32 (100)               |         |
| Surgeon                        | 5 (4.3)           | 5 (6.0)                   | 0                      |         |
| Performing EUS                 | 102 (88.7)        | 75 (90.4)                 | 27 (84.4)              | 0.35    |
| If you perform EUS, roughly how many EUS investigations do you perform weekly |                   |                           |                        | 0.03    |
| Under 5                        | 52 (50.9)         | 31 (41.3)                 | 21 (77.7)              |         |
| 6–10                           | 24 (23.6)         | 20 (26.7)                 | 2 (7.5)                |         |
| 11–20                          | 20 (19.7)         | 18 (24)                   | 2 (7.5)                |         |
| 21–30                          | 5 (4.9)           | 5 (6.7)                   | 0                      |         |
| More than 31                   | 1 (0.9)           | 1 (1.3)                   | 0                      |         |

Values are presented as number (%).
TA, tertiary/academic; PS, primary/secondary; EUS, endoscopic ultrasound.
forming EUS (88.7%). Compared to the respondents from the TA medical center, fewer respondents from primary/secondary (PS) care centers were performing more than six examinations of EUS a week (53% vs. 18.8%, respectively; \( p = 0.03 \)). The respondents reported that the patients with PCNs who were referred to the hospital were mostly identified by contrast-enhanced computed tomography (CE-CT) (57.4%) or by trans-abdominal ultrasound (38.2%). Most practitioners (65.2%) followed the 2012/2017 IAP guidelines for the management of PCNs. There was no significant difference in preferred practice guidelines between practitioners at the TA medical center and at the PS care center (\( p = 0.67 \)) (Fig. 1).

**Imaging modalities**

For the initial work-up of PCNs, a gadolinium-enhanced magnetic resonance imaging/magnetic resonance cholangiopancreatography (GE-MRI/MRCP) (40.9%) was preferred over non-enhanced MRI/MRCP (12.2%), CE-CT (22.6%), EUS (23.5%), or endoscopic retrograde cholangiopancreatography (0.9%) (Fig. 2). Regarding the follow-up modalities, however, 58.3% of the respondents mainly used CE-CT over other imaging studies, regardless of hospital type (Fig. 3).

**Contrast-enhanced EUS and EUS-guided fine needle aspiration**

Fifty-three respondents reported using contrast-enhanced EUS (CE-EUS) for evaluation of PCNs, especially in cases of suspicious mural nodules. TA medical respondents significantly favored using CE-EUS compared with respondents from the PS care center (54.2% vs. 25%, respectively; \( p = 0.004 \)). A large proportion of both groups (77.1%, TA medical center vs. 65.6%, PS care center) indicated that they performed EUS-fine needle aspiration (FNA) for PCNs with suspicious mural nodules. Nearly all subjects routinely checked for cystic fluid carcinoembryonic antigen (CEA) (95.7%) followed by cytology (94.8%). Most reported that prophylactic antibiotic administration (73.9%) and cessation of anticoagulant/antiplatelet agents (92.2%) prior to the EUS-FNA was implemented (Table 2). In total, 20 respondents experienced EUS-FNA-related adverse events including bleeding (n = 6), pancreatitis (n = 6), infection (n = 2), abdominal pain due to pancreatic juice leakage (n = 3), and perforation (n = 3).

**Surveillance and surgical referral patterns**

The surveillance strategies and surgical referral patterns are shown in Table 3. Regarding 2 to 3 cm sized PCNs, most respondents suggested a surveillance interval of 6 months (66.1%); the remainder chose 3 months (29.6%), or 1 year
In cases of PCN with main pancreatic duct (MPD) dilation (5 to 9 mm), most (80%) followed up at 6-monthly intervals. The 81.7% of the respondents would refer a patient to surgery for a PCN with high-risk stigmata. A larger proportion of the respondents from PS care center recommended surgery even if the PCNs had worrisome features (18.3%, TA medical center vs. 31.2%, PS care center, \( p = 0.03 \)). Most respondents (96.5%) would continue surveillance of PCNs for more than 5 years. Guidelines for the surveillance interval in PCNs with cysts sized 2 to 3 cm, or with MPD dilation of 5 to 9 mm are shown in Table 4. Of those who followed the 2012/2017 IAP guidelines, the 2018 American College Gastroenterology (ACG) clinical guideline, or the 2018 European guidelines, adherent to PCN with 2 to 3 cm or MPD dilation (5 to 9 mm) was 94.6%, 90.9%, and 100%, or 90.6%, 86.3%, and 72.2%, respectively.

**DISCUSSION**

As the prevalence of PCNs increased, several groups published their guidelines for management of PCNs. These guidelines are similar in many respects but considerable differences exist, including surveillance strategies and additional interventions. In our survey, most respondents followed the 2012/2017 IAP guidelines to manage the patients with PCNs, regardless of subspecialty or type of hospital. Most PCNs were initially identified by CE-CT (57.4%) or by trans-abdominal ultrasound (38.3%). A GE-MRI/MRCP (40.9%) was mainly used as a diagnostic imaging modality for better characterization of PCNs. However, the question on subsequent follow-up imaging modalities indicated that a CE-CT (58.3%) was used most commonly. Westerveld et al. [8] evaluated the practice pattern for the evaluation and management of incidental pancreatic cysts on survey. The author reported that MRI was the preferred modality for PCNs surveillance in most respondents (83.1%). In a different survey, assessing the approach of Dutch gastroenterologists in the management of asymptomatic PCNs, Hol et al. [9] found that EUS (39% and 57%) was considered as more a sensitive surveillance technique than CT (19% and 13%) or MRI/MRCP (22% and 22%) when evaluating 10 and 25 mm PCNs.

Most guidelines recommend the use of MRI/MRCP as an imaging tool for diagnosis and surveillance, primarily because of their non-invasiveness, lack of exposure to radiation, and greater sensitivity for identifying communication between the cyst and the pancreatic duct system. In contrast to the recommendations from several guidelines, a CE-CT was preferred as a subsequent follow-up imaging modality in this survey. Although the reason for their choice was not questioned in the survey, these findings may result from considering the economic burden. The national health insurance system in Korea was changed in November 2019...
to cover MRCP assessments for PCNs. GE-MRCP or MRCP is expected to be increasingly used as preferred follow-up imaging modality for PCNs in Korea.

The presence of mural nodules in PCNs is considered as high-risk stigmata by the IAP guidelines. However, it may be difficult to determine whether mural nodule-like lesions are truly mural nodules or mucus plugs. A CE-EUS allows to distinguish a true mural nodule from a mucus plug by identifying the microvasculature within the lesions [10-12]. Thus, a CE-EUS can identify the target lesion for EUS-FNA and avoid unnecessary puncture of the mucus plug. The recent guidelines have also recommended a CE-EUS for further evaluation of mural nodules in PCNs [4,6,7]. However, a CE-EUS remains unable to differentiate between serous and mucinous PCNs, due to similarity of enhancement patterns, including in the cystic walls and the septum [11,13]. In our survey, TA medical respondents used CE-EUS significantly more often than PS care center respondents (54.2% vs. 25%, respectively; \( p = 0.004 \)). This result may be attributable to some PS care centers, not having CE-EUS-enabled equipment and the high cost of CE-EUS. The clear indication or superiority of CE-EUS for the evaluation PCNs have not yet been established to date. In addition, there is a lack of appropriate education program on CE-EUS.

Table 2. Clinical practice of endoscopic diagnostic modalities for evaluation of pancreatic cystic neoplasms

| Characteristic | Overall (n = 115) | TA medical center (n = 83) | PS care center (n = 32) | \( p \) value |
|---------------|------------------|---------------------------|------------------------|-------------|
| Performing CE-EUS for evaluation of PCNs | 53 (46.1) | 45 (54.2) | 8 (25.0) | 0.004 |
| When do you perform CE-EUS for evaluation of PCNs (select all that apply) | | | | |
| Routinely during EUS | 1 (1.9) | 1 (2.2) | 0 | 0.560 |
| Routinely during EUS-FNA | 7 (13.2) | 6 (13.3) | 1 (12.5) | 0.949 |
| Suspicious mural nodule | 51 (96.2) | 44 (97.8) | 7 (87.5) | 0.235 |
| \( \geq 5 \) mm MPD diameter | 5 (9.4) | 4 (8.9) | 1 (12.5) | 0.756 |
| \( \geq 3 \) cm in cystic size | 10 (18.9) | 9 (20) | 1 (12.5) | 0.602 |
| When do you perform EUS-FNA for evaluation of PCNs (select all that apply) | | | | |
| For differential diagnosis for PCNs | 47 (40.9) | 32 (38.6) | 15 (46.9) | 0.526 |
| Suspicious mural nodule | 85 (73.9) | 64 (77.1) | 21 (65.6) | 0.240 |
| \( \geq 5 \) mm MPD diameter | 14 (12.2) | 11 (13.3) | 3 (9.4) | 0.750 |
| \( \geq 3 \) cm in cystic size | 40 (34.8) | 27 (32.5) | 13 (40.6) | 0.510 |
| \( \geq 5 \) mm/2 year in cyst growth rate | 34 (29.6) | 24 (28.9) | 10 (31.3) | 0.820 |
| Preoperative evaluation | 8 (7.0) | 7 (8.4) | 1 (3.1) | 0.440 |
| Antibiotic prophylaxis prior to EUS-FNA | 85 (73.9) | 65 (78.3) | 20 (62.5) | 0.100 |
| Anti-anticoagulant/antiplatelet agent cessation prior to EUS-FNA | 106 (92.2) | 76 (91.6) | 30 (93.8) | 0.730 |
| Preferred cystic fluid analysis (select all that apply) | | | | |
| Cytology | 109 (94.8) | 79 (95.2) | 30 (93.8) | 0.670 |
| Biopsy | 31 (27) | 22 (26.5) | 9 (28.1) | 0.860 |
| CEA | 110 (95.7) | 80 (96.4) | 30 (93.8) | 0.610 |
| Amylase | 101 (87.8) | 73 (88.0) | 28 (87.5) | 0.940 |
| Ancillary test (e.g., molecular analysis) | 5 (4.3) | 4 (4.8) | 1 (3.1) | 0.680 |

Values are presented as number (%).

TA, tertiary/academic; PS, primary/secondary; CE-EUS, contrast-enhanced endoscopic ultrasound; PCN, pancreatic cystic neoplasm; EUS-FNA, endoscopic ultrasound-guided fine needle aspiration; MPD, main pancreatic duct; CEA, carcinoembryonic antigen.
ther studies and education programs on CE-EUS are needed.

EUS-FNA can differentiate between mucinous and non-mucinous cysts and between malignant and benign lesions. Evaluation techniques of aspiration cystic fluid, including color, viscosity, intra-cystic CEA, and cytology, are widely used to evaluate PCNs. In particular, the diagnostic yield of cytology for PCNs with suspicious mural nodules or masses are reported to be up to 89.6% [14]. However, the sensitivity of cystic fluid cytology is relatively low in the case of PCNs without mural nodules, and consensus on the cutoff level of cystic fluid CEA for differentiating mucinous from non-mucinous cysts has not yet been achieved [15]. To overcome these problems, various devices or novel techniques have been investigated, but more research is needed to elucidate a gold standard method [16]. Our findings showed that most respondents analyzed the EUS-FNA cytology and intra-cystic CEA levels for cystic fluid analysis, as in many

### Table 3. Surveillance strategies and surgical referral pattern of pancreatic cystic neoplasm

| Characteristic                                                                 | Overall (n = 115) | TA medical center (n = 83) | PS care center (n = 32) | p value |
|--------------------------------------------------------------------------------|-------------------|-----------------------------|-------------------------|---------|
| What time interval would you choose for surveillance in 2–3 cm PCNs            |                   |                             |                         | 0.240   |
| Every 3 months                                                                 | 34 (29.6)         | 24 (28.9)                   | 10 (31.3)               |         |
| Every 6 months                                                                 | 76 (66.1)         | 54 (65.1)                   | 22 (68.7)               |         |
| Every year                                                                     | 5 (4.3)           | 5 (6.0)                     | 0                       |         |
| What time interval would you choose for surveillance in PCNs with MPD dilation (5–9 mm) |                   |                             |                         | 0.970   |
| Every 3 months                                                                 | 10 (8.7)          | 7 (8.4)                     | 3 (9.4)                 |         |
| Every 6 months                                                                 | 92 (80)           | 66 (79.6)                   | 26 (81.2)               |         |
| Every years                                                                    | 13 (11.3)         | 10 (12.0)                   | 3 (9.4)                 |         |
| Do you follow-up PCNs for more than 5 years                                    |                   |                             |                         | 0.065   |
| Yes                                                                            | 111 (96.5)        | 82 (98.9)                   | 29 (90.6)               |         |
| No                                                                             | 4 (3.5)           | 1 (1.2)                     | 3 (9.4)                 |         |
| When would you usually recommend surgery                                        |                   |                             |                         | 0.030   |
| High-risk stigmata[A]                                                          | 94 (81.7)         | 72 (86.7)                   | 22 (68.8)               |         |
| Worrisome features[B]                                                          | 21 (18.3)         | 11 (13.3)                   | 10 (31.2)               |         |

Values are presented as number (%).

TA, tertiary/academic; PS, primary/secondary; PCN, pancreas cystic neoplasm; MPD, main pancreatic duct.

A High-risk stigmata including obstructive jaundice due to cyst, enhancing mural nodule (≥ 5 mm), MPD dilation (≥ 10 mm) [6].

B Worrisome features including cyst (≥ 3 cm), enhancing mural nodule (≤ 5 mm), MPD dilation (5 to 6 mm), cyst growth rate ≥ 5 mm/2 years, thickened/enhancing cyst walls, abrupt change in pancreatic duct diameter with distal pancreatic atrophy, lymphadenopathy, increased serum level of CA 19-9 [6].

### Table 4. Adherence of surveillance interval to guidelines for management of pancreatic cystic neoplasms

|                      | 2012/2017 IAP guideline (n = 75) | 2018 ACG clinical guideline (n = 22) | 2018 European guideline (n = 18) |
|----------------------|----------------------------------|-------------------------------------|---------------------------------|
| Minimum surveillance |                                  |                                     |                                 |
| 2–3 cm in a cyst size| 71 (94.6)                        | 20 (90.9)                           | 18 (100)                        |
| 5–9 mm in MPD diameter| 68 (90.6)                        | 19 (86.3)                           | 13 (72.2)                       |

Values are presented as number (%).

IAP, International Association of Pancreatology; ACG, American College Gastroenterology; MPD, main pancreatic duct.
There is no strict indication for EUS-FNA in PCNs. Westerveld et al. [8] reported that about half of the participants in the PCNs management survey would routinely perform EUS-FNA for the evaluation of PCNs without a mural nodule, solid component, or MPD dilation. The indications of EUS-FNA may vary slightly, depending on the guidelines. In particular, guidelines differ regarding the use of EUS-FNA for high-risk lesions, such as those with mural nodules. American and European guidelines support EUS-FNA in lesions appearing to be high-risk. However, the IAP guidelines recommend surgical management of high-risk lesions without EUS-FNA, because of possible peritoneal seeding from the leakage of fluid contents by EUS-FNA [18,19]. From this survey, many respondents followed the IAP guidelines, but, contrary to the guideline recommendations, most of the EUS-FNA for PCNs were performed in cases of suspicious mural nodules in current practice. Explanations for this discrepancy may be as follows (1) these procedures rarely lead to EUS-FNA related tumor dissemination in subsequent studies (2) difficulties in determining surgery without pathologic evaluation (3) [19,20]. Furthermore, the performance of EUS-FNA may vary by PCN location, but the current study did not include this factor.

The major concern of EUS-FNA for PCNs is procedure-related adverse events. In a large prospective study, the overall rate of EUS-FNA-related adverse events was 6% [21]. The most common adverse event was bleeding (2.35%), followed by infection (1.34%), and pancreatitis (0.67%). Administration of prophylactic antibiotics, and discontinuation of anticoagulant/antiplatelet drugs after tailored thrombotic risk assessment, are recommended in most guidelines to reduce the risk of bleeding or infection, although conclusive evidence is lacking [4,22,23]. In our survey, 20 respondents experienced EUS-FNA-related adverse events including bleeding, pancreatitis, infection, abdominal pain due to pancreatic juice leakage, and perforation. Prophylactic antibiotic administration and cessation of anticoagulant/antiplatelet agents prior to the EUS-FNA were generally performed in our survey.

The current survey showed relatively high rates of guideline adherence for the surveillance interval in PCNs with cysts sized 2 to 3 cm or with MPD dilation (5 to 9 mm). However, our findings differed from those of previous studies. Schenck et al. [24] evaluated the guideline adherence to major published guidelines on PCNs. Of those who received surveillance, only 66% were monitored with minimally appropriate follow-up per any guideline. Therefore, authors concluded that adherence to guideline surveillance for PCNs was poor. Tabrizian et al. [25] also demonstrated poor compliance with clinical guidelines for management of IPMNs in real practice. In real-world practice, besides considering guidelines, decision-making about treatment and surveillance strategies for PCNs consider various factors including age, comorbidities, location of the lesion, and socioeconomic status. Therefore, management for PCNs can make it difficult to follow the guidelines, even if clinicians attempt to adhere. In the current study, our survey questionnaires for surveillance interval included cyst size or MPD diameter but no other clinical factors such as life expectancy, cyst location, or comorbidities. For these reasons, there may be a difference between the healthcare provider-based current survey results and patient-based clinical researches.

Differences in clinical practice between TA medical respondents and those from PS care centers existed in the surgical referral pattern. Our findings demonstrated that TA medical respondents were significantly less likely to recommend surgery in the case of worrisome features than were respondents from PS care centers (18.3% vs. 31.2%, respectively; p = 0.03). In clinical practice, pancreatic surgery is rarely performed in PS care centers because of its significant morbidity and mortality, and a lack of surgical staff. In addition, compared to TA medical centers, PS care centers have insufficient medical staff and equipment to enable additional tests including EUS, CE-EUS, or EUS-FNA for evaluating PCNs with worrisome features. These real points can make it difficult for the respondents from PS care centers to perform regular surveillance for patients with PCNs with malignant potential, such as those with worrisome features. Thus, many patients with PCNs with worrisome features in PS care centers may be transferred to TA medical centers for second opinion, which may lead to surgery. Furthermore, TA medical practitioners may have more expertise with EUS, greater experience, and better knowledge of PCNs. It is assumed that these practical issues caused some difference in the surgical referral pattern between the two groups.

In the current survey, five surgeons participated and no significant differences including preferred guidelines, surveillance strategies, and surgical referral patterns for the management of PCNs were found between the gastroenterologist and surgeon (Supplementary Table 1). These
findings may reflect the bridging of the gap between two groups in the management of PCNs. However, it is difficult to fully accept these results because there were limitations associated with the statistical analyses including the small sample size and the fact that different results might have been obtained if more surgeons had participated.

Practice patterns for the management of PCNs, especially in the intensity of surveillance or surgical referral pattern, may be affected by the age of the practitioners. In the present study, in comparison with old practitioners (> 50 years), there was no significant difference in other practice patterns; however, younger practitioners (31 to 50 years) observed PCNs with cysts sized 2 to 3 cm or with MPD dilation (5 to 9 mm) in shorter intervals (Supplementary Table 2). These results may reflect the difference in the level of experience. Another possible explanation is that younger practitioners tend to be more concerned about malignant transformation of PCNs due to the paucity of well-established guidelines.

To date, studies on practice patterns related to the management of PCNs are limited. This is the first national survey in Korea to assess the actual clinical patterns for management of PCNs. However, several limitations still exist. First, the survey was restricted to the members of KPBA, thereby introducing selection bias in our cohort. Therefore, the generalizability of our survey results to practice patterns in other countries is uncertain. Second, the response rate was suboptimal, and thus a response bias may occur. The potential distortion of the survey outcomes may exist in the absence of analyzable data for non-respondents. Third, recall and reporting bias may occur, as in other all surveys.

In conclusion, this study identified differences in PCN management among the respondents. In addition, some aspects in a real clinical setting vary considerably from the recommendations of existing guidelines. Therefore, evidence-based guidelines for PCNs that fit the Korean practice are needed to establish an optimal approach to the management of PCNs.

**KEY MESSAGE**

1. Clinicians’ management strategies of pancreatic cystic neoplasms (PCNs) slightly vary according to their preferred guideline, experience, or type of hospital in Korea.
2. Korean clinician showed relatively high rates of PCNs guideline adherence, but there were several differences between real clinical practice and the recommendations of existing guidelines.
3. Continuous efforts to develop the evidenced-based guidelines for PCNs that fit the Korean practice are needed.

**Conflicts of interest**

No potential conflict of interest relevant to this article was reported.

**Acknowledgements**

We thank all respondents of this study and Policy-Quality management members of the Korean Pancreatobiliary Association and study personal for their contribution to the study.

**REFERENCES**

1. Chang YR, Park JK, Jang JY, Kwon W, Yoon JH, Kim SW. Incidental pancreatic cystic neoplasms in an asymptomatic healthy population of 21,745 individuals: large-scale, single-center cohort study. Medicine (Baltimore) 2016;95:e5535.
2. de Jong K, Nio CY, Hermans JJ, et al. High prevalence of pancreatic cysts detected by screening magnetic resonance imaging examinations. Clin Gastroenterol Hepatol 2010;8:806-811.
3. Scholten L, van Huijgevoort NCM, van Hooft JE, Besselink MG, Del Chiaro M. Pancreatic cystic neoplasms: different types, different management, new guidelines. Visc Med 2018;34:173-177.
4. European Study Group on Cystic Tumours of the Pancreas. European evidence-based guidelines on pancreatic cystic neoplasms. Gut 2018;67:789-804.
5. Cho CS, Russ AJ, Loeffler AG, et al. Preoperative classification of pancreatic cystic neoplasms: the clinical significance of diagnostic inaccuracy. Ann Surg Oncol 2013;20:3112-3119.
6. Tanaka M, Fernandez-Del Castillo C, Kamisawa T, et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology 2017;17:738-753.
7. Elta GH, Enestvedt BK, Sauer BG, Lennon AM. ACG clinical guideline: diagnosis and management of pancreatic cysts. Am
8. Westerveld D, Goddard A, Harris N, et al. Survey study on the practice patterns of the evaluation and management of incidental pancreatic cysts. Dig Dis Sci 2019;64:689-697.

9. Hol L, Bruno MJ, Cahen DL. Follow-up of asymptomatic pancreatic cysts in clinical practice: a vignette questionnaire. Panreatology 2016;16:416-422.

10. Yamashita Y, Ueda K, Itonaga M, et al. Usefulness of contrast-enhanced endoscopic sonography for discriminating mural nodules from mucous clots in intraductal papillary mucinous neoplasms: a single-center prospective study. J Ultrasound Med 2013;32:61-68.

11. Hocke M, Cui XW, Domagk D, Ignee A, Dietrich CF. Pancreatic cystic lesions: the value of contrast-enhanced endoscopic ultrasound to influence the clinical pathway. Endosc Ultrasound 2014;3:123-130.

12. Kamata K, Kitano M, Omoto S, et al. Contrast-enhanced harmonic endoscopic ultrasonography for differential diagnosis of pancreatic cysts. Endoscopy 2016;48:35-41.

13. Fusaroli P, Serrani M, De Giorgio R, et al. Contrast harmonic-endoscopic ultrasound is useful to identify neoplastic features of pancreatic cysts (with videos). Pancreas 2016;45:265-268.

14. Shirley LA, Walker J, Krishna S, et al. Routine cyst fluid cytology is not indicated in the evaluation of pancreatic cystic lesions. J Gastrointest Surg 2016;20:1581-1585.

15. Larino-Noia J, Iglesias-Garcia J, de la Iglesia-Garcia D, Dominguez-Munoz JE. EUS-FNA in cystic pancreatic lesions: where are we now and where are we headed in the future? Endosc Ultrasound 2018;7:102-109.

16. Alvarez-Sanchez MV, Napoleon B. New horizons in the endoscopic ultrasonography-based diagnosis of pancreatic cystic lesions. World J Gastroenterol 2018;24:2853-2866.

17. Chin YK, Wu CCH, Tan DMY. The role of needle-based confocal laser endomicroscopy in the evaluation of pancreatic cystic lesions: a systematic review. Clin Endosc 2021;54:38-47.

18. Yamao K, Yanagisawa A, Takahashi K, et al. Clinicopathological features and prognosis of mucinous cystic neoplasm with ovarian-type stroma: a multi-institutional study of the Japan pancreas society. Pancreas 2011;40:67-71.

19. Yoon WJ, Dagliilar ES, Fernandez-del Castillo C, Minokud- son M, Pitman MB, Brugge WR. Peritoneal seeding in intraductal papillary mucinous neoplasm of the pancreas patients who underwent endoscopic ultrasound-guided fine-needle aspiration: the PIPE Study. Endoscopy 2014;46:382-387.

20. Gleeson FC, Lee JH, Dewitt JM. Tumor seeding associated with selected gastrointestinal endoscopic interventions. Clin Gastroenterol Hepatol 2018;16:1385-1388.

21. Tarantino I, Fabbri C, Di Mitri R, et al. Complications of endoscopic ultrasound fine needle aspiration on pancreatic cystic lesions: final results from a large prospective multicenter study. Dig Liver Dis 2014;46:41-44.

22. Jacobson BC, Baron TH, Adler DG, et al. ASGE guideline: the role of endoscopy in the diagnosis and the management of cystic lesions and inflammatory fluid collections of the pancreas. Gastrointest Endosc 2005;61:363-370.

23. Polkowski M, Larghi A, Weynand B, et al. Learning, techniques, and complications of endoscopic ultrasound (EUS)-guided sampling in gastroenterology: European Society of Gastrointestinal Endoscopy (ESGE) Technical Guideline. Endoscopy 2012;44:190-206.

24. Schenck RJ, Miller FH, Keswani RN. The surveillance patterns of incidentally detected pancreatic cysts vary widely and infrequently adhere to guidelines. Pancreas 2019;48:883-887.

25. Tabrizian P, Berger Y, Pierobon ES, et al. Are clinical guidelines for the management of intraductal papillary mucinous neoplasms followed?: a single-center analysis. Pancreas 2017;46:198-202.
### Supplementary Table 1. Comparison of gastroenterologists and surgeons in the management of pancreatic cystic neoplasms

| Variable                                                       | Gastroenterologist (n = 110) | Surgeon (n = 5) | p value |
|----------------------------------------------------------------|------------------------------|-----------------|---------|
| Sex, male/female                                               | 106/4                        | 5/0             | 0.547   |
| Age, yr                                                        |                              |                 | 0.201   |
| 31–40                                                         | 32 (29.1)                    | 1 (20)          |         |
| 41–50                                                         | 44 (40.0)                    | 4 (80)          |         |
| 51–60                                                         | 29 (26.4)                    | 0               |         |
| 60 or more                                                    | 5 (4.5)                      | 0               |         |
| Type of hospital                                               |                              |                 | 0.067   |
| PS                                                            | 32 (29.1)                    | 0               |         |
| TA                                                            | 78 (70.9)                    | 5 (100)         |         |
| Preferred guidelines                                          |                              |                 | 0.111   |
| 2012/2017 IAP                                                  | 70 (63.6)                    | 5 (100)         |         |
| 2018 ACG                                                      | 22 (20.0)                    | 0               |         |
| 2018 European                                                 | 18 (16.4)                    | 0               |         |
| Preferred initial imaging modalities                          |                              |                 | 0.747   |
| Enhanced CT                                                   | 24 (21.8)                    | 2 (40)          |         |
| GE-MRI/MRCP                                                   | 45 (40.9)                    | 2 (40)          |         |
| MRI/MRCP                                                      | 14 (12.7)                    | 0               |         |
| EUS                                                           | 26 (23.6)                    | 1 (20)          |         |
| ERCP                                                          | 1 (0.9)                      | 0               |         |
| Preferred follow-up imaging modalities                        |                              |                 | 0.200   |
| Enhanced CT                                                   | 62 (56.4)                    | 5 (100)         |         |
| GE-MRI/MRCP                                                   | 12 (10.9)                    | 0               |         |
| MRI/MRCP                                                      | 19 (17.3)                    | 0               |         |
| EUS                                                           | 11 (10.0)                    | 0               |         |
| US                                                            | 6 (17.3)                     | 0               |         |
| What time interval would you choose for surveillance in 2–3 cm PCNs |                              |                 | 0.790   |
| Every 3 months                                                | 32 (30.1)                    | 2 (40)          |         |
| Every 6 months                                                | 79 (66.4)                    | 3 (60)          |         |
| Every year                                                    | 5 (4.5)                      | 0               |         |
| What time interval would you choose for surveillance in PCNs with MPD dilation (5–9 mm) |                              |                 | 0.480   |
| Every 3 months                                                | 10 (9.1)                     | 0               |         |
| Every 6 months                                                | 77 (79.1)                    | 5 (100)         |         |
| Every years                                                   | 13 (11.8)                    | 0               |         |
| Do you follow-up PCNs for more than 5 years                   |                              |                 | 0.547   |
| Yes                                                           | 106 (96.4)                   | 5 (100)         |         |
| No                                                            | 4 (3.6)                      | 0               |         |
| When would you usually recommend surgery                      |                              |                 | 0.801   |
| High-risk stigmata\(^a\)                                      | 90 (91.8)                    | 4 (80)          |         |
| Worrisome features\(^b\)                                     | 20 (18.2)                    | 1 (20)          |         |

Values are presented as number (%).

PS, primary/secondary; TA, tertiary/academic; IAP, International Association of Pancreatology; ACG, American College of Gastroenterology; CT, computed tomography; GE-MRI, gadolinium-enhanced magnetic resonance imaging; MRCP, magnetic resonance cholangiopancreatography; EUS, endoscopic ultrasound; ERCP, endoscopic retrograde choangiopancreatography; US, ultrasound; PCN, pancreas cystic neoplasm; MPD, main pancreatic duct.

\(^a\)High-risk stigmata including obstructive jaundice due to cyst, enhancing mural nodule (≥ 5 mm), MPD dilation (≥ 10 mm) [6].

\(^b\)Worrisome features including cyst (≥ 3 cm), enhancing mural nodule (≤ 5 mm), MPD dilation (5–6 mm), cyst growth rate ≥ 5 mm/2 years, thickened/enhancing cyst walls, abrupt change in pancreatic duct diameter with distal pancreatic atrophy, lymphadenopathy, increased serum level of CA 19-9 [6].

https://doi.org/10.3904/kjim.2020.452
Supplemental Table 2. Comparison of clinical practice according to the age groups in the management of pancreatic cystic neoplasms

| Variable | Young\(^a\) participants (n = 81) | Old\(^b\) participants (n = 34) | p value |
|----------|----------------------------------|----------------------------------|---------|
| Sex, male/female | 79/2 | 32/2 | 0.580 |
| Specialty | | | 0.320 |
| Gastroenterologist | 76 (93.8) | 34 (100) | |
| Surgeon | 5 (6.2) | 0 | |
| Type of hospital | | | 0.903 |
| PS | 24 (29.6) | 8 | |
| TA | 57 (70.4) | 26 (76.5) | |
| Performing EUS | 71 (87.7) | 31 (91.2) | 0.752 |
| Preferred guidelines | | | 0.255 |
| 2012/2017 IAP | 56 (69.1) | 19 (55.9) | |
| 2018 ACG | 15 (18.5) | 7 (20.6) | |
| 2018 European | 10 (12.3) | 8 (23.5) | |
| Preferred initial imaging modalities | | | 0.509 |
| Enhanced CT | 15 (18.5) | 11 (32.4) | |
| GE-MRI/MRCP | 33 (40.7) | 14 (41.2) | |
| MRI/MRCP | 11 (13.6) | 3 (8.8) | |
| EUS | 21 (25.9) | 6 (17.6) | |
| ERCP | 1 (1.2) | 0 | |
| Preferred follow-up imaging modalities | | | 0.433 |
| Enhanced CT | 51 (63) | 16 (47.1) | |
| GE-MRI/MRCP | 6 (7.4) | 6 (17.6) | |
| MRI/MRCP | 12 (14.8) | 7 (20.6) | |
| EUS | 8 (9.9) | 3 (8.8) | |
| US | 4 (4.9) | 2 (5.9) | |
| What time interval would you choose for surveillance in 2–3 cm PCNs | | | 0.085 |
| Every 3 months | 29 (35.8) | 5 (14.7) | |
| Every 6 months | 49 (60.5) | 27 (79.4) | |
| Every year | 3 (3.7) | 2 (5.9) | |
| What time interval would you choose for surveillance in PCNs with MPD dilation (5–9 mm) | | | 0.009 |
| Every 3 months | 10 (12.3) | 0 | |
| Every 6 months | 64 (79) | 28 (82.3) | |
| Every years | 7 (8.7) | 6 (17.1) | |
| Do you follow-up PCNs for more than 5 years | | | 0.317 |
| Yes | 77 (95.1) | 34 (100) | |
| No | 4 (3.6) | 0 | |
| When would you usually recommend surgery | | | 0.593 |
| High-risk stigmata\(^c\) | 66 (81.5) | 28 (82.4) | |
| Worrisome features\(^d\) | 15 (18.5) | 6 (17.6) | |

Values are presented as number (%).
PS, primary/secondary; TA, tertiary/academic; EUS, endoscopic ultrasound; IAP, International Association of Pancreatology; ACG, American College Gastroenterology; CT, computed tomography; GE-MRI/MRCP, gadolinium-enhanced magnetic resonance imaging/magnetic resonance cholangiopancreatography; ERCP, endoscopic retrograde choangiopancreatography; US, ultrasound; PCN, pancreas cystic neoplasm; MPD, main pancreatic duct.

\(^a\)Participants aged 31 to 50 years were categorized as young.

\(^b\)Participants aged 50 above were categorized as old.

\(^c\)High-risk stigmata including obstructive jaundice due to cyst, enhancing mural nodule (≥ 5 mm), MPD dilation (≥ 10 mm) [6].

\(^d\)Worrisome features including cyst (≥ 3 cm), enhancing mural nodule (≤ 5 mm), MPD dilation (5–6 mm), cyst growth rate ≥ 5 mm/2 years, thickened/enhancing cyst walls, abrupt change in pancreatic duct diameter with distal pancreatic atrophy, lymphadenopathy, increased serum level of CA 19-9 [6].
APPENDIX 1.

1. What is your gender?
   ① Male ② Female

2. What is your age?
   ① 31–40
   ② 41–50
   ③ 51–60
   ④ 60 or more

3. What is your specialty?
   ① Gastroenterologist
   ② Surgeon
   ③ Other

4. In what kind of hospital are you currently working?
   ① Primary/Secondary care center
   ② Tertiary/Academic medical center
   ③ Other, please specify:

5. Do you perform endoscopic ultrasounds?
   ① Yes  ② No

6. If you perform EUS, roughly how many EUS investigations do you perform weekly?
   ① Under 5
   ② 6–10
   ③ 11–20
   ④ 21–30
   ⑤ More than 31

7. Which of the following guidelines do you choose to manage pancreas cystic neoplasms?
   ① 2012/2017 International Association of Pancreatologists Guideline
   ② 2018 European evidence-based Guideline
   ③ 2018 American College of Gastroenterology Clinical Guideline
   ④ 2015 American Gastroenterological Association Institute Guideline
   ⑤ Others

8. Which of the following modalities usually first found the patient with suspicious pancreas cystic neoplasms?
   ① Abdominal ultrasound

9. Which imaging modality would you use as first-line evaluation for pancreatic cystic neoplasms?
   ① Contrast-enhanced computed tomography
   ② Magnetic resonance imaging/magnetic resonance cholangiopancreatography
   ③ Endoscopic ultrasound

10. When do you perform contrast-enhanced endoscopic ultrasound for evaluation of pancreatic cystic neoplasms (select all that apply)?
    ① Routinely during endoscopic ultrasound
    ② Routinely during endoscopic ultrasound-guided fine needle aspiration
    ③ Suspicious mural nodule
    ④ ≥ 5 mm MPD diameter
    ⑤ ≥ 3 cm in cystic size
    ⑥ Never

11. When do you perform endoscopic ultrasound-guided fine needle aspiration for evaluation of pancreatic cystic neoplasms (select all that apply)?
    ① For differential diagnosis for pancreas cystic neoplasms
    ② Suspicious mural nodule
    ③ ≥ 5 mm MPD diameter
    ④ 3 cm in cystic size
    ⑤ ≥ 5 mm/2 year in cyst growth rate
    ⑥ Preoperative evaluation

12. Do you use antibiotic prophylaxis when performing endoscopic ultrasound-guided fine needle aspiration for evaluation of pancreatic cystic neoplasms?
    ① Yes  ② No

13. Do you discontinue anticoagulant/antiplatelet agents prior to endoscopic ultrasound-guided fine needle aspiration for evaluation of pancreatic cystic neoplasms?
14. Which of the following tests would you use for cystic fluid analysis (select all that apply)?
   ① Cytology
   ② Biopsy
   ③ Cystic fluid carcinoembryonic antigen
   ④ Cystic fluid amylase
   ⑤ Ancillary test (e.g. molecular analysis)

15. When would you usually recommend surgery?
   ① High-risk stigmata
   ② Worrisome features
   ③ Patient anxiety
   ④ Pancreatic cystic neoplasms located in the pancreatic body or tail
   ⑤ Others

   ① High-risk stigmata including obstructive jaundice due to cyst, enhancing mural nodule (≥ 5 mm), MPD dilation (≥ 10 mm).
   ② Worrisome features including cyst (≥ 3 cm), enhancing mural nodule (≤ 5 mm), MPD dilation (5–6 mm), cyst growth rate ≥ 5 mm/2 years, thickened/enhancing cyst walls, abrupt change in pancreatic duct diameter with distal pancreatic atrophy, lymphadenopathy, increased serum level of CA 19-9.

16. Which imaging modality would you use for subsequent surveillance?
   ① Abdominal ultrasound
   ② Contrast-enhanced computed tomography
   ③ Magnetic resonance imaging/magnetic resonance cholangiopancreatography
   ④ Gadolinium-enhanced magnetic resonance imaging/magnetic resonance cholangiopancreatography
   ⑤ Endoscopic ultrasound

17. What time interval would you choose for surveillance in 2–3 cm pancreatic cystic neoplasms?
   ① Every 3 months
   ② Every 6 months
   ③ Every year
   ④ Every 2 years
   ⑤ Others

18. What time interval would you choose for surveillance in pancreatic cystic neoplasms with main pancreatic duct dilation (5–9 mm)?
   ① Every 3 months
   ② Every 6 months
   ③ Every year
   ④ Every 2 years
   ⑤ Others

19. Do you follow up pancreas cystic neoplasms for more than five years?
   ① Yes  ② No

20. Do you have any experience with endoscopic ultrasound-related severe adverse events in the past year?
   ① Never
   ② Hemorrhage
   ③ Infection
   ④ Acute pancreatitis
   ⑤ Perforation
   ⑥ Others